CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease
- Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC)
- CANbridge holds exclusive Greater China license to maralixibat (CAN108) in liver diseases, China trial ongoing in biliary atresia (BA)
Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT).
To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China